The Pharmacy Times® Respiratory Syncytial Virus Resource Center is a comprehensive source for clinical news and expert insights on treating and preventing respiratory syncytial virus.
April 25th 2024
The severity of RSV disease among adults further highlights how crucial vaccine polices and recommendations are.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Community Pharmacists and Technicians: Impacting Public Health One Service at a Time
Community-based pharmacy services are reaching new heights as pharmacists and pharmacy technicians are able to have a larger impact on patient care than ever before.
Read More
Immunoprophylaxis Guidance for RSV Not Aligned With Current Hospitalization Patterns, Study Finds
July 12th 2023Investigators urge policymakers to establish flexible models that maximize coverage when respiratory syncytial virus activity is high and minimize unnecessary doses when viral activity is low.
Read More
Patient-Reported Questionnaire Could Aid the Evaluation of Respiratory Syncytial Virus Symptoms
June 30th 2023Findings suggest that psychometric tests used for The Respiratory Infection Intensity and Impact Questionnaire provide reliable, construct validity, and responsive evidence to detect onset symptoms of RSV.
Read More
ACIP Votes to Recommend Use of Arexvy for Respiratory Syncytial Virus in Older Adults
June 22nd 2023CDC Advisory Committee on Immunization Practices recommends the use of respiratory syncytial virus (RSV) vaccine, adjuvanted (Arexvy) for adults 60 years of age and older based on findings from the first season of the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial.
Read More
Lipid Nanoparticles Could Be Effective Carriers for mRNA Vaccines for Viral Lung Infections
May 19th 2023Nanoparticles could improve the solubility of drugs, aid in treatment escape from the immune system, and increase the half-life of drugs in the circulatory system against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus.
Read More
FDA Approves First Respiratory Syncytial Virus Vaccine for Adults Aged 60 Years and Older
May 3rd 2023Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Read More